Vera Therapeutics Inc (NASDAQ: VERA) on Monday, plunged -5.45% from the previous trading day, before settling in for the closing price of $22.57. Within the past 52 weeks, VERA’s price has moved between $18.53 and $51.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 4.49%. The company achieved an average annual earnings per share of -55.42%. With a float of $48.53 million, this company’s outstanding shares have now reached $63.82 million.
Let’s determine the extent of company efficiency that accounts for 112 employees.
Vera Therapeutics Inc (VERA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vera Therapeutics Inc is 23.96%, while institutional ownership is 89.02%. The most recent insider transaction that took place on Jun 23 ’25, was worth 4,369,676. In this transaction Director of this company bought 209,393 shares at a rate of $20.87, taking the stock ownership to the 3,569,522 shares. Before that another transaction happened on Jun 24 ’25, when Company’s Director bought 40,607 for $22.35, making the entire transaction worth $907,635. This insider now owns 3,596,593 shares in total.
Vera Therapeutics Inc (VERA) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.85 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.62) by -0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -55.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.39% during the next five years compared to 4.49% growth over the previous five years of trading.
Vera Therapeutics Inc (NASDAQ: VERA) Trading Performance Indicators
Vera Therapeutics Inc (VERA) is currently performing well based on its current performance indicators. A quick ratio of 16.92 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.58, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -4.51 in one year’s time.
Technical Analysis of Vera Therapeutics Inc (VERA)
Looking closely at Vera Therapeutics Inc (NASDAQ: VERA), its last 5-days average volume was 1.98 million, which is a jump from its year-to-date volume of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 58.19%.
During the past 100 days, Vera Therapeutics Inc’s (VERA) raw stochastic average was set at 19.42%, which indicates a significant decrease from 47.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.06 in the past 14 days, which was lower than the 1.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.10, while its 200-day Moving Average is $29.92. However, in the short run, Vera Therapeutics Inc’s stock first resistance to watch stands at $22.31. Second resistance stands at $23.27. The third major resistance level sits at $23.78. If the price goes on to break the first support level at $20.84, it is likely to go to the next support level at $20.33. Now, if the price goes above the second support level, the third support stands at $19.37.
Vera Therapeutics Inc (NASDAQ: VERA) Key Stats
Market capitalization of the company is 1.36 billion based on 63,824K outstanding shares. Right now, sales total 0 K and income totals -152,150 K. The company made 0 K in profit during its latest quarter, and -76,530 K in sales during its previous quarter.
